
ANI Pharmaceuticals reports outcomes from diabetic macular oedema trial
ANI Pharmaceuticals has disclosed the outcomes of its randomised NEW DAY trial, assessing Iluvien 0.19mg, in people with diabetic macular oedema (DME). The multicenter, prospective, masked, active-controlled trial involved 306 eyes from patients who were …